PUBLIC COMPANY
save$SLSSELLAS Life Sciences Group, Inc.
$SLS13.40-3.25%New York, NY, USupdated 4h ago
community read0 votes
pipeline
3
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Preclinical1Phase 21Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Active trials
- phase2Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- —Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS
- phase3Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
- phase2WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
- phase2Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
- phase2Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
- phase2WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 29m ago
Found something off?
comments(0)
5-min edit window · permanent after that